Hologic acquires Reveal Genomics

✦ Meridian Analysis

Hologic’s acquisition of Barcelona‑based Reveal Genomics is now signed, pending the usual regulatory clearances and customary closing conditions. The deal brings Reveal’s four genomic‑test products – notably the HER2DX assay for HER2‑positive breast cancer – under the umbrella of Hologic, a Nasdaq‑listed leader in women’s health technologies that was taken private by Blackstone and TPG. For Hologic, the purchase adds a precision‑oncology portfolio that complements its existing diagnostic devices. The transaction is structured as a straight asset purchase; financing details have not been disclosed, and the company has a €2 million participatory loan from Avançsa. Earlier this month Meridian reported EQT’s €10.8 bn buyout of a German diagnostics group. Reveal already holds U.S. regulatory clearances and is finalising CE marking for the European market. Deal professionals will be watching for the undisclosed purchase price and any earn‑out or milestone components tied to Reveal’s product pipeline, as well as the composition of the advisory and financing teams. Confirmation of antitrust approvals, the timeline for integrating Reveal’s assays into Hologic’s global sales network, and the impact on Hologic’s post‑buyout capital structure remain to be clarified.

The Meridian Weekly